- Novo Nordisk will acquire Dicerna for $3.3 billion in cash.
- The acquisition makes sense for Novo Nordisk as it eliminates the milestones and royalties it would need to pay Dicerna for partnered candidates.
- The deal also brings Dicerna's wholly-owned hepatic and extrahepatic drug discovery platform and pipeline and potential milestones and royalties from several partners.
- Based on the broad potential of Dicerna's pipeline, I believe Novo Nordisk is getting a bargain.
- A higher bid could emerge but chances are slim and the deal should close soon.
For further details see:
Novo Nordisk Gets A Bargain With Dicerna Acquisition